Photobiomodulation reduces the cytokine storm syndrome associated with Covid-19 in the zebrafish model (original) (raw)
Related papers
The Effectiveness of Photobiomudulation therapy (PBMT) in COVID-19 Infection
Journal of Lasers in Medical Sciences, 2020
Introduction: Currently, the COVID-19 pandemic is an important health challenge worldwide. Due to the cytokine storm, the mortality rate in acute respiratory distress syndrome (ARDS) is high, but until now no therapy for these patients was approved. The aim of this review was to discuss the possible anti-inflammatory effect of photobiomodulation therapy (PBMT) on ARSD patients and present the potential role of low-level laser therapy (LLLT) in the improvement of respiratory symptoms associated with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: Studies about PBMT in inflammation and ARSD patients were examined. A primary search with reviewing English-language citations between 2005 and 2020 using the keywords COVID-19, ADRS, cytokine storm, low-level laser therapy, anti-inflammatory, and photobiomodulation was performed. The initial search yielded 818 articles; however, 60 articles were selected and discussed in the present study. Results: The results of the selected studies showed the usefulness of PBMT in the treatment of inflammation and ARSD in patients with COVID-19 infection. This therapy is non-invasive and safe to modulate the immune responses in ARSD patients. Conclusion: PBMT can potentially reduce the viral load and bacterial super-infections in patients with COVID-19 infection and control the inflammatory response. Therefore, the use of PBMT could be an efficient strategy for preventing severe and critical illness in SARS-COV2 infection.
International Journal of Molecular Sciences
Researchers from across the world are seeking to develop effective treatments for the ongoing coronavirus disease 2019 (COVID-19) outbreak, which arose as a major public health issue in 2019, and was declared a pandemic in early 2020. The pro-inflammatory cytokine storm, acute respiratory distress syndrome (ARDS), multiple-organ failure, neurological problems, and thrombosis have all been linked to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fatalities. The purpose of this review is to explore the rationale for using photobiomodulation therapy (PBMT) of the particular wavelength 1068 nm as a therapy for COVID-19, investigating the cellular and molecular mechanisms involved. Our findings illustrate the efficacy of PBMT 1068 nm for cytoprotection, nitric oxide (NO) release, inflammation changes, improved blood flow, and the regulation of heat shock proteins (Hsp70). We propose, therefore, that PBMT 1068 is a potentially effective and innovative approach for avoiding s...
Photobiomodulation Therapy as a Possible New Approach in COVID-19: A Systematic Review
Life
COVID-19 is a viral disease characterized as a pandemic by the World Health Organization in March 2020. Since then, researchers from all over the world have been looking for ways to fight this disease. Many cases of complications arise from insufficient immune responses due to low immunity, with intense release of pro-inflammatory cytokines that can damage the structure of organs such as the lung. Thus, the hypothesis arises that photobiomodulation therapy (PBMT) with the use of a low-level laser (LLLT) may be an ally approach to patients with COVID-19 since it is effective for increasing immunity, helping tissue repair, and reducing pro-inflammatory cytokines. This systematic review was performed with the use of PubMed/MEDLINE, Web of Science, Scopus and Google Scholar databases with the following keywords: “low-level laser therapy OR photobiomodulation therapy AND COVID-19”. The inclusion criteria were complete articles published from January 2020 to January 2021 in English. The e...
Frontiers in Neuroscience, 2023
There is an urgent need for therapeutic approaches that can prevent or limit neuroinflammatory processes and prevent neuronal degeneration. Photobiomodulation (PBM), the therapeutic use of specific wavelengths of light, is a safe approach shown to have anti-inflammatory effects. The current study was aimed at evaluating the effects of PBM on LPS-induced peripheral and central inflammation in mice to assess its potential as an anti-inflammatory treatment. Daily, 30-min treatment of mice with red/NIR light (RL) or RL with a 40 Hz gamma frequency flicker for 10 days prior to LPS challenge showed anti-inflammatory effects in the brain and systemically. PBM downregulated LPS induction of key proinflammatory cytokines associated with inflammasome activation, IL-1β and IL-18, and upregulated the anti-inflammatory cytokine, IL-10. RL provided robust anti-inflammatory effects, and the addition of gamma flicker potentiated these effects. Overall, these results demonstrate the potential of PBM as an anti-inflammatory treatment that acts through cytokine expression modulation.
Lasers in Medical Science, 2018
Sepsis is a big health problem and one of the most common causes of acute lung injury (ALI) leading to high mortality. Proresolving mediators play an important role in abrogating the inflammation and promoting tissue homeostasis restoration. ALI treatment is still a clinical health problem, so new therapies are needed. Here, we evaluated the effect of photobiomodulation treatment on the resolution process of ALI induced by lipopolysaccharide (LPS). Male Balb/c mice were submitted to LPS (ip) or vehicle and irradiated or not with light emitting diode (LED) 2 and 6 h after LPS or vehicle injection, and the parameters were investigated 3 and 7 days after the injections. Our results showed that after 3 days of LED treatment the blood and bronchoalveolar lavage (BAL) cells as well as interleukins (IL) including IL-6 and IL-17 were reduced. No differences were observed in the bone marrow cells, tracheal reactivity, and lipoxin A4 and resolvin E2. Indeed, after 7 days of LED treatment the bone marrow cells, lymphocytes, and lipoxin A4 were increased, while IL-6, IL-17, and IL-10 were decreased. No differences were observed in the blood cells and tracheal reactivity. Thus, our results showed that LED treatment attenuated ALI induced by sepsis by modulating the cell mobilization from their reserve compartments. In addition, we also showed later effects of the LED up to 7 days after the treatment. This study proposes photobiomodulation as therapeutic adjuvant to treat ALI.
Effects of Intravenous Photobiomodulation Therapy in the Management of Patients with COVID-19
Archives of clinical infectious diseases, 2024
Background: The symptoms of coronavirus disease 2019 (COVID-19) range from asymptomatic to severe respiratory distress or death. Reviews on potential COVID-19 treatments show no established therapy. Photobiomodulation can help in reducing inflammation and speed up tissue repair. In addition, due to its few side effects, it appears to be effective in restricting COVID-19. Therefore, it was decided to use this method in disease control to achieve the systemic impact of intravascular photobiomodulation therapy in this study. Methods: A total of 60 patients were randomly divided into three groups of 20 subjects: A control group that received common treatments for COVID-19, a group treated with a low-power gallium arsenide laser diode (660 nm) with an output dose of 2 J/cm 2 for 7 minutes and 5 days in a row in addition to standard treatments, and another group that received common treatments with the same laser dose at the same time as the first group with a low-power diode laser (450 nm). Laboratory data and clinical criteria between groups were compared before and after the treatment. Results: An increase in O2 and partial pressure of oxygen (PO2) was significant in the two laser therapy groups (P < 0.05). In addition, the partial pressure of carbon dioxide (PCO2) decreased significantly in the blue laser group (mean difference =-1.44 ± 12.72). The COP score was reduced in all groups; however, only in the blue laser group the reduction in COP score was significant (P < 0.05). In the blue laser group, the COP score before and after the treatment was reduced. Conclusions: The use of an intravenous laser with red and blue wavelength with an output dose of 2 J/cm 2 for 7 minutes and 5 days in a row, in addition to standard treatments, showed the improvement of oxygenation (O2 and PO2 in arterial blood gas [ABG]) and the reduction of inflammatory factors (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) and COP scores. However, further extensive studies are needed to prove the therapeutic effects of intravenous lasers, along with the usual treatments for COVID-19.
Antioxidants
The COVID-19 pandemic has taken the entire globe by storm. The pathogenesis of this virus has shown a cytokine storm release, which contributes to critical or severe multi-organ failure. Currently the ultimate treatment is palliative; however, many modalities have been introduced with effective or minimal outcomes. Meanwhile, enormous efforts are ongoing to produce safe vaccines and therapies. Phototherapy has a wide range of clinical applications against various maladies. This necessitates the exploration of the role of phototherapy, if any, for COVID-19. This critical review was conducted to understand COVID-19 disease and highlights the prevailing facts that link phototherapy utilisation as a potential treatment modality for SARS-CoV-2 viral infection. The results demonstrated phototherapy’s efficacy in regulating cytokines and inflammatory mediators, increasing angiogenesis and enhancing healing in chronic pulmonary inflammatory diseases. In conclusion, this review answered the ...
Photobiomodulation therapy reduces acute pain and inflammation in mice
Journal of Photochemistry and Photobiology B-biology, 2019
Photobiomodulation (PBM) is a therapy suggested for the treatment of pain and inflammation. Different mechanisms have been proposed to explain the analgesic and inflammatory effects of photobiomodulation, but there are still gaps on the mechanisms underlying. The objective was to investigate the analgesic and anti-inflammatory effect of red LED, as well as to investigate the possible mechanism of action in acute nociception models. Radiation was applied with red LED (660nm, 215mW, 84.64mW/cm², 2.531J/cm² (30s); 5.07J/cm 2 (60s) 7.61J/cm² (90s) and 10.15J/cm² (120s)). The red LED applied 60 seconds before the experiments, promoted reduction of
Oxidative Medicine and Cellular Longevity, 2021
Chemicals and signaling molecules released by injured cells at the beginning of wound healing prompt inflammation. In diabetes, prolonged inflammation is one of the probable causes for delayed wound healing. Increased levels of cyclooxygenase-2 (cox-2), interleukin–6 (IL-6), and tumour necrosis factor-alpha (TNF-α) are associated with the inflammatory response and in diabetes, and increased levels of these contribute to chronic wounds that do not heal. Rising levels of cox-2, IL-6, and TNF-α have also been associated with increased oxidative stress. Photobiomodulation (PBM) may impact wound healing processes by affecting the signaling pathways and molecules pertinent to tissue repair. In the present study, the effect of PBM (wavelength: 660 nm; energy density: 5 J/cm2) on levels of cox-2, IL-6, and TNF-α was determined in fibroblast cell culture models. Four WS1 models (normal, normal wounded, diabetic, and diabetic wounded) were irradiated at 660 nm, and the culture media was colle...
Background There is an urgent need for therapeutic approaches that can prevent or limit neuroinflammatory processes and prevent neuronal degeneration. Photobiomodulation (PBM), the therapeutic use of specific wavelengths of light, is a safe approach shown to have anti-inflammatory effects. The current study was aimed at evaluating the effects of PBM on LPS-induced peripheral and central inflammation in mice to assess the potential of PBM as an anti-inflammatory treatment. Methods Effects of PBM were evaluated in group-housed C57BL/6J mice. Mice were divided into three groups: (a) a control group receiving no PBM, (b) a group receiving PBM utilizing red/NIR light at 640 and 880 nm (RL), and (c) a group receiving RL with a 40 Hz gamma frequency flicker (RLG). PBM was administered over 12 days (5 days per week for 2 weeks; no treatment on days 6 and 7). Each PBM treatment was 30 minutes. On day 11, mice were dosed by intraperitoneal injection with either vehicle or LPS (1 mg/kg). Brain...